Testagen
Also known as: Lys-Glu-Asp-Gly
A Khavinson tetrapeptide (Lys-Glu-Asp-Gly) developed in Russia as a tissue-specific bioregulator targeting prostate and testicular tissue. Promoted for supporting age-related decline in male reproductive and urinary function. Sits in the same Khavinson family as the other tissue-specific cytogens. Western clinical evidence is limited.
Dosage
Fixed dose: 100-200 mg oral daily for 10-30 day cycles
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Half-Life
Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure
Half-Life Calculator →Administration
Oral capsule or subcutaneous injection (cycled)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Prostate Support
Khavinson tetrapeptide proposed to support prostate epithelial function in age-related decline.
Sexual Health
Russian observational studies report improvements in urinary and sexual function indices in elderly men.
Tissue-Specific Bioregulation
Proposed gene-expression effects on testicular and prostate tissue via promoter binding.
Mechanism of Action
Testagen is a short Khavinson tetrapeptide (Lys-Glu-Asp-Gly) positioned as the male reproductive and prostate tissue bioregulator within the wider Khavinson peptide family. The proposed mechanism is consistent with the family-wide model: short peptides interact with gene promoter regions in target tissue cells, modulating tissue-specific gene expression patterns to support normal cellular function and counteract age-related decline.
Proposed targets include genes regulating prostate epithelial proliferation and differentiation, androgen receptor signalling sensitivity, and local immune function within prostatic and testicular tissue. Russian research groups have reported testagen-induced improvements in indices of urinary and sexual function in elderly men with age-related prostatic and testicular decline, and animal studies have suggested effects on testicular function markers and prostate gland histology.
As with all Khavinson bioregulators, the published efficacy evidence sits almost entirely within Russian gerontology research traditions and has not been replicated in independent Western randomised controlled trials. Importantly, testagen is not validated for the prevention or treatment of prostate cancer or benign prostatic hyperplasia, and its safety in men with hormone-sensitive cancers has not been established. Use should not displace evidence-based urology care, and users with prostate concerns should consult a urologist rather than relying on bioregulator protocols.
Regulatory Status
Not FDA approved. Sold as a research peptide and as a registered nutritional supplement in Russia. Available internationally through Khavinson-affiliated suppliers.
Risks & Safety
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; not validated for prostate cancer prevention or treatment, and any effect on hormone-sensitive tissues remains uncharacterised in rigorous trials.
Rare
allergic reactions. Should not replace evidence-based urology care.
Compare Testagen With
Research Papers
2Published: July 26, 2025
AI Summary
Electrochemistry and DFT/Monte Carlo modelling showed Testagen (Lys-Glu-Asp-Gly) adsorbs spontaneously to copper and inhibits corrosion in saline by ~86%. The work characterises the peptide chemically rather than for human use.
Published: November 1, 2011
AI Summary
Fluorescence-labelled Testagen (Lys-Glu-Asp-Gly) penetrated HeLa cell nuclei and bound DNA preferentially at CAG-containing motifs. The sequence-specific binding supports an epigenetic mechanism for its biological effects.
Frequently Asked Questions
What is Testagen?
A Khavinson tetrapeptide (Lys-Glu-Asp-Gly) developed in Russia as a tissue-specific bioregulator targeting prostate and testicular tissue. Promoted for supporting age-related decline in male reproductive and urinary function. Sits in the same Khavinson family as the other tissue-specific cytogens. Western clinical evidence is limited.
What is Testagen used for?
A Khavinson tetrapeptide (Lys-Glu-Asp-Gly) developed in Russia as a tissue-specific bioregulator targeting prostate and testicular tissue. Promoted for supporting age-related decline in male reproductive and urinary function. Sits in the same Khavinson family as the other tissue-specific cytogens. Western clinical evidence is limited.
What is the dosage for Testagen?
Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Cycling protocol consistent with the Khavinson family.
What are the side effects of Testagen?
Common: generally reported as well tolerated. Serious: very limited Western clinical data; not validated for prostate cancer prevention or treatment, and any effect on hormone-sensitive tissues remains uncharacterised in rigorous trials. Rare: allergic reactions. Should not replace evidence-based urology care.
How does Testagen work?
Testagen is a short Khavinson tetrapeptide (Lys-Glu-Asp-Gly) positioned as the male reproductive and prostate tissue bioregulator within the wider Khavinson peptide family. The proposed mechanism is consistent with the family-wide model: short peptides interact with gene promoter regions in target tissue cells, modulating tissue-specific gene expression patterns to support normal cellular function and counteract age-related decline. Proposed targets include genes regulating prostate epithelial proliferation and differentiation, androgen receptor signalling sensitivity, and local immune function within prostatic and testicular tissue. Russian research groups have reported testagen-induced improvements in indices of urinary and sexual function in elderly men with age-related prostatic and testicular decline, and animal studies have suggested effects on testicular function markers and prostate gland histology. As with all Khavinson bioregulators, the published efficacy evidence sits almost entirely within Russian gerontology research traditions and has not been replicated in independent Western randomised controlled trials. Importantly, testagen is not validated for the prevention or treatment of prostate cancer or benign prostatic hyperplasia, and its safety in men with hormone-sensitive cancers has not been established. Use should not displace evidence-based urology care, and users with prostate concerns should consult a urologist rather than relying on bioregulator protocols.
How is Testagen administered?
Testagen is administered via oral capsule or subcutaneous injection (cycled).
What is the half-life of Testagen?
The half-life of Testagen is Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure.
Is Testagen legal?
Not FDA approved. Sold as a research peptide and as a registered nutritional supplement in Russia. Available internationally through Khavinson-affiliated suppliers.
Sources. This profile is built from peer-reviewed papers indexed on PubMed, FDA-approved labelling where available, and published clinical guidelines. The 2 primary sources used are listed in the Research Papers section above, each linked to its PubMed entry. See our editorial standards for how we research and review peptide profiles.
Last reviewed. by the Peptide Reference Editorial Team. Spot an error? Email a correction.
Not medical advice. Information on this page is for educational and research reference only. Many peptides covered are not approved for human use. See our full medical disclaimer.
Related Peptides
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.
Alprostadil
A medication that treats erectile dysfunction by relaxing the blood vessels in the penis, allowing blood to flow in and create an erection. Unlike pills that require arousal to work, this works directly at the injection or application site — you don't need to be in the mood. Available as an injection into the penis or as a small pellet inserted into the urethra.
Bronchogen
A Khavinson tetrapeptide (Ala-Glu-Asp-Leu) developed in Russia as a tissue-specific bioregulator targeting the lungs and respiratory tract. Promoted for chronic respiratory conditions, age-related decline in lung function, and recovery from respiratory illness. Like the other Khavinson cytamins, the evidence base is dominated by Russian research and not independently validated in Western clinical practice.
CJC-1295 (no DAC)
One of the most popular growth hormone peptides, often called Mod GRF 1-29. Instead of injecting growth hormone directly, this tells your pituitary gland to release more of its own GH naturally. This is considered healthier than injecting GH directly because your body keeps its normal feedback systems intact. Usually combined with Ipamorelin for much stronger effects — the two work together better than either alone.